白蛋白结合型紫杉醇治疗晚期恶性肿瘤45例临床观察  

Clinical observation of albumin-bound paclitaxel on 45 patients with advanced malignant tumors

作　　者：张珺[1] 殷铁军[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院综合科,湖北武汉430030

出　　处：《中国医院药学杂志》2014年第5期392-395,共4页Chinese Journal of Hospital Pharmacy

基　　金：湖北省人口和计划生育委员会科研基金资助(编号:JS-20130019)

摘　　要：目的:观察白蛋白结合型紫杉醇治疗晚期恶性肿瘤的有效性和安全性。方法:经病理组织学或细胞学检查确诊的晚期恶性肿瘤患者45例,其中18例接受白蛋白结合型紫杉醇单药化疗,剂量为130 mg·m-2,加入生理盐水100 ml中静脉滴注,第1和8天给药;27例接受白蛋白结合型紫杉醇联合化疗,奈达铂75 mg·m-2加入生理盐水250 ml中静脉滴注,第1或8天给药,每21天为1周期。按照WHO标准评价近期疗效和毒性反应,Karnofsky评分(KPS)变化评价生活质量(QOL)。用药1周期评价毒性,2周期后评价疗效。结果:全组45例患者共完成化疗189个周期,平均4.2周期/例,均可评价近期疗效和安全性。其中获CR1例,PR18例,SD20例,PD6例,即RR为42.2%(19/45),DCR为86.7%(39/45);22例(48.9%)QOL改善,20例(44.4%)QOL稳定,仅3例(6.7%)QOL下降;Ⅲ/Ⅳ级毒性的发生率为26.7%(12/45),多为中性粒细胞减少。结论:白蛋白结合型紫杉醇对晚期恶性肿瘤有较好疗效,可以改善和稳定晚期恶性肿瘤患者的生活质量,治疗耐受性良好,值得临床推广应用和深入观察。OBJECTIVE To observe the efficacy and safety of albumin-bound paclitaxel on 45 cases of patients with advanced malignancies. METHODS Albumin-bound paclitaxel were administrated to 45 malignant cases confirmed by histopathology or cytopathology every 3 weeks. The efficacy and quality of life （QOL）） were evaluated according to WHO criteria and Karnofsky scores after 2 cycles. The safety was evaluated according to WHO criteria after 1 cycle. RESULTS Totally 189 cycles were completed and mean cycle was 4. 2. Among 45 cases, there was 1 case achieved CR, 18 cases of PR, 20 cases of SD, and 6 ca ses of PD. The response rate was 42. 2% （19/45） and the disease control rate was 86. 7% （39/45）. The quality of life were improved on 22 cases （48. 9%）, stabled on 20 cases （44. 4%）, and decreased on 3 cases （6. 7%）. The occurrence rates of G Ill/IV toxicities were 26. 7% （12/45）. The predominant adverse events were neutropenia. CONCLUSION The albumin-bound paclitaxel is effective and tolerable in patients with advanced malignancies. QOL of patients may be improved by the therapy of albumin-bound paclitaxel. It is worthy of clinical generalization and further clinical observation.

关 键 词：白蛋白结合型紫杉醇 化疗 晚期恶性肿瘤 

分 类 号：R730.53[医药卫生—肿瘤]